Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Average Rating of “Moderate Buy” from Analysts

by · The Cerbat Gem

Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Free Report) has earned an average recommendation of “Moderate Buy” from the six research firms that are presently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation, three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $44.25.

A number of brokerages have recently weighed in on COLL. Weiss Ratings reissued a “hold (c+)” rating on shares of Collegium Pharmaceutical in a report on Monday. Wall Street Zen upgraded Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Needham & Company LLC reiterated a “buy” rating and issued a $46.00 price target on shares of Collegium Pharmaceutical in a report on Tuesday, October 28th. Zacks Research upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 21st. Finally, Truist Financial upped their price objective on shares of Collegium Pharmaceutical from $45.00 to $48.00 and gave the company a “buy” rating in a report on Friday, November 7th.

Get Our Latest Stock Report on COLL

Insider Buying and Selling

In other Collegium Pharmaceutical news, CFO Colleen Tupper sold 30,000 shares of the stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $40.53, for a total transaction of $1,215,900.00. Following the sale, the chief financial officer directly owned 126,667 shares of the company’s stock, valued at approximately $5,133,813.51. This trade represents a 19.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 2.51% of the company’s stock.

Institutional Trading of Collegium Pharmaceutical

Several hedge funds and other institutional investors have recently bought and sold shares of COLL. Illinois Municipal Retirement Fund lifted its holdings in Collegium Pharmaceutical by 1.6% in the third quarter. Illinois Municipal Retirement Fund now owns 17,281 shares of the specialty pharmaceutical company’s stock valued at $605,000 after acquiring an additional 278 shares during the period. Vident Advisory LLC increased its holdings in shares of Collegium Pharmaceutical by 1.9% during the 3rd quarter. Vident Advisory LLC now owns 15,466 shares of the specialty pharmaceutical company’s stock valued at $541,000 after purchasing an additional 281 shares in the last quarter. Federated Hermes Inc. lifted its stake in shares of Collegium Pharmaceutical by 67.0% in the 3rd quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company’s stock valued at $31,000 after purchasing an additional 350 shares during the period. Assetmark Inc. boosted its holdings in Collegium Pharmaceutical by 8.4% during the third quarter. Assetmark Inc. now owns 4,551 shares of the specialty pharmaceutical company’s stock worth $159,000 after buying an additional 352 shares in the last quarter. Finally, Franklin Resources Inc. grew its position in Collegium Pharmaceutical by 1.4% during the second quarter. Franklin Resources Inc. now owns 29,172 shares of the specialty pharmaceutical company’s stock valued at $863,000 after buying an additional 409 shares during the period.

Collegium Pharmaceutical Trading Up 1.0%

NASDAQ COLL opened at $46.68 on Friday. Collegium Pharmaceutical has a 12-month low of $23.23 and a 12-month high of $48.18. The company has a fifty day simple moving average of $38.10 and a two-hundred day simple moving average of $34.65. The company has a current ratio of 1.36, a quick ratio of 1.27 and a debt-to-equity ratio of 2.71. The stock has a market cap of $1.48 billion, a P/E ratio of 28.99 and a beta of 0.61.

Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) last announced its quarterly earnings data on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 earnings per share for the quarter. The firm had revenue of $135.55 million for the quarter. Collegium Pharmaceutical had a net margin of 7.72% and a return on equity of 102.03%. On average, analysts forecast that Collegium Pharmaceutical will post 5.62 earnings per share for the current year.

About Collegium Pharmaceutical

(Get Free Report)

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.

Featured Stories